EHA
June 17, 2020
Virtual 25th Annual European Hematology Association (EHA) Congress, June 11-21, 2020
Year
2020
Target
RVU120 (CDK8/CDK19), daposertib (MEN1703 / SEL24), PIM/FLT3
Assets in this page
Download assets
- pdf file
“A First-in-human study of SEL120, a novel oral selective CDK8/19 inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome”
Download - pdf file
"Results of the dose escalation part of DIAMOND trial (CLI24-001): first in human study of SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor, in Patients with Acute Myeloid Leukemia"
Download